Keynote address: Perspectives on the use of interleukin-2 in cancer treatment

Cancer Journal from Scientific American

Volumn 3, Issue SUPPL. 1, 1997, Pages

  Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; MELANOMA ANTIGEN; RECOMBINANT INTERLEUKIN 2;

ADVANCED CANCER; ARTICLE; BOLUS INJECTION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; MELANOMA; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE;

CARCINOMA, RENAL CELL; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; KIDNEY NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED;

EID: 0031424935     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Rosenberg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 1994;271:907-913.
2. Schwartzentruber DJ. Biologic therapy with interleukin-2: clinical applications. In: DeVita V, Hellman S, Rosenberg SA, eds. Biologic Therapy of Cancer (2nd ed). Philadelphia: Lippincott, 1995:235-249.
3. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986;233:1318-1321.
4. Itoh K, Tilden AB, Balch CM. Interleukin-2 activation of cytotoxic T-1 infiltrating into human metastatic melanomas. Cancer Res 1986;46:3011-3017.
5. Muul LM, Spiess PJ, Director EP et al. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 1987;138:989-995.
6. Rosenberg SA, Packard BS, Aebersold PM et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: preliminary report. N Engl J Med 1988;319:1676-1680.
7. Rosenberg SA, Yannelli JR, Yang JC et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst 1994;86: 1159-1166.
8. Fisher B, Packard BS, Read EJ et al. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol 1989;7: 250-261.
9. Griffith KD, Read EJ, Carrasquillo JA et al. In vivo distribution of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. J Natl Cancer Inst 1989;81:1709-1717.
10. Boon T. Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy. Int J Cancer 1993;54:177-180.
11. Kawakami Y, Eliyahu S, Delgado CH et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A 1994;91:6458-6462.
12. Kawakami Y, Eliyahu S, Delgado CH et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A 1994;91:3515-3519.
13. Robbins PF, El-Gamil M, Li Y et al. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol 1995;154: 5944-5950.
14. Wang RF, Robbins PF, Kawakami Y et al. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 1995;181: 799-804.
15. Robbins PF, El-Gamil M, Li YF et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996;183:1185-1192.
16. Robbins PF, El-Gamil M, Kawakami Y et al. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res 1994;54:3124-3126.
17. Parkhurst MR, Salgaller ML, Southwood S et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A* 0201-binding residues. J Immunol 1996;157:2539-2548.
18. Cormier JN, Salgaller ML, Prevette T et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A Cancer J Sci Am 1997;3:37-44.
19. Salgaller ML, Marincola FM, Cormier JN et al. Immunization against epitopes in the human melanoma antigen gpl00 following patient immunization with synthetic peptides. Cancer Res 1996; 56:4749-4757.